

# Y90 Segmentectomy and Lobectomy: My Top-5 Tips

Sid Padia, MD

Professor of Radiology

Director of IR, UCLA Santa Monica

UCLA

# Disclosures

**Sid Padia, MD:** Consultant – Boston Scientific, Bristol Meyer Squibb; Grant/Research Support – Varian Medical Systems

*Brand names are included in this presentation for participant clarification purposes only.  
No product promotion should be inferred.*

# Top-5 Tips

1. All the work is in the mapping angiogram. The treatment is a breeze.
2. If you are not doing cone-beam CT routinely, you are below the standard of care.
3. Small microcatheters for segmental vessels; large microcatheters for lobar vessels
4. Don't be afraid of giving high doses.
5. Radiation lobectomy doesn't necessarily always have to get surgery.


1. All the work is in the mapping angiogram. The treatment is a breeze.

Mapping angiogram minimum:



- SMA
- Celiac
- Common/Proper hepatic artery
- Left hepatic artery
- Middle hepatic artery
- Right hepatic artery
- Cone-beam CT
- Segmental catheterization



Two hypervascular tumors  
Segment 7  
Segment 6





RIGHT



RHA 2/12

RIGHT



Middle hepatic artery  
1/6



2. If you are not doing cone-beam CT routinely, you are below the standard of care.

## Goals of CBCT?

- Restage the patient
- Possibly better define indeterminate lesions
- Identify arterial feeders to tumors



Combined arterial and parenchymal phase in one scan

# CBCT Variables

Every machine is different: You must be familiar with your settings.



1. Acquisition time (4-10 seconds)
2. Contrast dilution
3. Contrast rate of injection
4. Acquisition delay time

# CBCT Example

- Philips
- Acquisition time = 4 seconds (need to breath-hold for liver)
- Contrast:
  - 2/3 strength (average size pt.)
  - Rate of injection: antegrade flow without reflux based on prior DSA
  - Delay time: start of tumor blush based on prior DSA


# CBCT Example

- Philips
- Acquisition time = 4 seconds (need to breath-hold for liver)
- Contrast:
  - 2/3 strength (average size pt)
  - Rate of injection: 2 cc/sec
  - Delay time: 3 seconds (start of tumor opacification)
- Acquire CT with contrast in the artery (arterial phase) and in the tumor (parenchymal phase)
- Total time = 7 seconds (3-sec. delay + 4-sec acq.) → 2/14 with 3-sec delay.



CBCT  
Right hepatic artery  
2/16  
4-sec. delay  
4-sec. acquisition





CBCT  
Right hepatic artery  
2/16  
4-sec. delay  
4-sec. acquisition

### 3. Small microcatheters for segmental vessels; large microcatheters for lobar vessels

Large = 2.8 French distal OD

PROGREAT  
Renegade HI-FLOW  
LANTERN

Medium = 2.4 Fr


PROGREAT 2.4  
Direxion 021

Small = 2.0 Fr

PROGREAT alpha  
TRUESELECT



Right hepatic artery







RIGHT

Y90  
Segment 6

5 F Simmons-1  
2.0 F TRUESELECT





RIGHT



Right lobar Y90  
PROGREAT 2.8 Fr

## 4. Don't be afraid of giving high doses (in the right patient)

Package insert:

Glass: 120 gray

Resin: BSA formula

Segmentectomy: > 400 Gy

Lobectomy: > 120 Gy or partition dosing

# LEGACY Trial

Patient Characteristics	Treated Population (N=162) N (%)
<b>Median age (range), years</b>	66 (21-90)
≥ 18 to < 65	69 (42.6)
≥ 65 to < 75	64 (39.5)
≥ 75	29 (17.9)
<b>Gender, male</b>	123 (75.9)
<b>HCC Etiology</b>	
HCV	112 (69.1)
Alcohol	48 (29.6)
NASH	23 (14.2)
HBV	15 (9.3)
Other/unknown	5 (3.1)
<b>ECOG Status</b>	
0	98 (60.5)
1	64 (39.5)
<b>BCLC Status</b>	
A	98 (60.5)
C	64 (39.5)
<b>AFP ≥ 200 ng/mL</b>	24 (14.8)

Treatment Characteristics	Treated Population (N=162) N (%)
<b>Median Tumor Size (range), cm</b>	2.6 (0.9-8.1)
<b>Initial Y90 Treatment Goal</b>	
Radiation segmentectomy	104 (64.2)
Radiation lobectomy	8 (5.0)
Bridge to liver transplantation	36 (22.2)
Other	1 (0.6)
Unknown	13 (8.0)
<b>Type of Infusion</b>	
Selective	155 (95.7)
Lobar	3 (1.9)
Mixed	4 (2.5)
<b>Absorbed dose to perfused liver volume (Gy), median, (IQR)</b>	410.1 (199.7, 797.7)
<b>Number of TheraSphere Treatments</b>	
1	130 (80.2)
≥2	32 (19.8)


# Yttrium-90 glass microspheres in the treatment of early and advanced hepatocellular carcinoma: data from the multicenter LEGACY study

Dr. Riad Salem, MD, MBA  
Northwestern University, Chicago, IL

On behalf of the LEGACY Study Investigators

CIRSE 2020 Summit

## Overall Survival: Disease Stage



	% Patients alive (95% CI)	
	24 M	36 M
Early HCC (BCLC A) (n=98)	92.8 (84.5, 96.7)	82.5 (69.9, 90.2)
Advanced HCC (BCLC C) (n=64)	98.0 (86.9, 99.7)	93.0 (79.7, 97.7)
All patients (n=162)	94.8 (89.5, 97.5)	86.6 (78.1, 92.0)



N At Risk	0	6	12	18	24	30	36	42	48	54	60
Early HCC	98	95	92	69	52	43	27	18	8	5	0
Advanced HCC	64	63	59	49	41	30	24	11	6	2	0
All Patients	162	158	151	118	93	73	51	29	14	7	0



# Factors Effecting Hypertrophy

Variables	Frequency of MHT $\geq 10\%$	Univariate analysis	Multivariate analysis
FLR <50% vs > 50%	92.4 vs 68.4%	$p = 0.0203$	$p = 0.0023$
HILD <88Gy vs $\geq 88$ Gy	65.7% vs 92.2	$p = 0.0081$	$p = 0.0029$
TD $\geq 205$ Gy and TV $\geq 100\text{cm}^3$ vs TD <205Gy or TV < 100 cm <sup>3</sup>	81.8 vs 75.8%	ns	–
HILD $\geq 88$ Gy or TD $\geq 205$ Gy for TV $\geq 100\text{cm}^3$ vs HILD <88Gy and TD <205Gy or TV < 100 cm <sup>3</sup>	83.9 vs 54.5%	$p = 0.0265$	not tested*
Child A5 vs A6 + B7	89.6 vs 40.0%	$p = 0.0001$	$p < 0.0001$
PVT present vs absent	81.8 vs 78.9%	ns	–
Hypersplenism present vs absent	71.4 vs 80.7%	ns	–
Response vs no response	81.4 vs 33.3%	ns	–
Liver toxicity vs no liver toxicity	75.0 vs 79.7%	ns	–
First line vs $\geq$ second line	72.9 vs 92.9%	ns, but trends ( $p = 0.0706$ )	–

- 73-patient study
- HCC
- Dose to tumor and liver calculated with MAA scan



Y90  
Segment 7 HCC


3 GBq in seg 7  
5 GBq in MHA




Single HCC with PVT

Potential candidate for right  
hepatectomy

Y90 or PVE?







Initial








175 Gray delivered to right hepatic lobe





Initial

4 months



Initial

24 months

## 5. Radiation lobectomy doesn't necessarily always have to get surgery

- Initially designed for patients to bridge or downstage to resection
- Many centers don't have experienced hepatic surgeons who want to do resection
- But what if they don't ever need surgery?

Include:



- Child Pugh A
- Unilobar disease
- Requires lobar treatment (not able to be segmental)

73-year-old male  
HBV Cirrhosis

Child A  
Portal HTN  
ECOG 0

Initial segment 8 HCC (4.3 cm)  
MWA 1/2017  
MWA for recurrence 3/17


Multifocal HCC, unilobar  
No PVT  
No mets  
**BCLC B**








180 Gray  
Right hepatic lobe




S/p right radiation lobectomy



Baseline


S/p right radiation lobectomy



Baseline

2 months

S/p right radiation lobectomy




Baseline


2 months

12 months


S/p right radiation lobectomy




Baseline



2 months



12 months



15 months

# Top-5 Tips

1. All the work is in the mapping angiogram. The treatment is a breeze.
2. If you are not doing cone-beam CT routinely, you are below the standard of care.
3. Small microcatheters for segmental vessels; large microcatheters for lobar vessels
4. Don't be afraid of giving very high doses.
5. Radiation lobectomy doesn't necessarily always have to get surgery.



# Thank you!



Sid Padia, MD  
spadia@mednet.ucla.edu

